Cite
HARVARD Citation
Lieberman, L. et al. (2016). CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Lieberman, L. et al. (2016). CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology. p. . [Online].